Chikusetsusaponin Iva
CAS No. : 51415-02-2
(Synonyms: Calenduloside F)
| Size | Price | Stock |
|---|---|---|
| 1mg | $85 | In-stock |
| 5mg | $180 | In-stock |
| 10mg | $264 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N0818 |
| M.Wt: | 794.97 |
| Formula: | C42H66O14 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a KD value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects[1][2][3][4][5][6][7][8][9][10].
In Vitro:Chikusetsusaponin Iva (12.5-50 μM; 24 h) induces apoptosis in endometrial cancer cells (HEC1B) via promoting ROS production[1].
Chikusetsusaponin IVa (3.75-60 μg/mL) shows inhibitory effects on H9N2 AIV in A549 cells, with TI values of 4.00 (co-treatment) and 6.29 (posttreatment)[2].
Chikusetsusaponin IVa (50-200 μg/mL; 24 h) shows inhibitory effects on lipopolysaccharide-induced proinflammatory responses in THP-1 cells[3].
Chikusetsusaponin IVa binds to YAP with a KD of 0.388 mM[4].
Chikusetsusaponin IVa (10-40 μM; 24 h) increases the viability of Palmitic acid (HY-N0830)-damaged HepG2 cells and primary mouse hepatocytes and reduces LDH levels in culture supernatants[6].
Chikusetsusaponin Iva (3.125-12.5 μg/mL; 1 h) inhibits inflammatory responses in LPS-stimulated RAW264.7 cell line by inhibiting MAPK pathway[7].
In Vivo:Chikusetsusaponin IVa (15-60 mg/kg; p.o.; once daily; 5 consecutive days) mitigates pulmonary impairment, improves the organism’s antioxidant activity, and regulates the Nrf2 and MAPK signaling pathways in lung tissue of H9N2 AIV-infected mice[2].
Chikusetsusaponin IVa (10-40 mg/kg; p.o.; daily; 14 days after BDL) significantly alleviates liver fibrosis and injury in CCl4 (HY-Y0298)-challenged and bile duct ligation (BDL)-induced liver fibrosis mouse models by downregulating YAP and TAZ expression[4].
Chikusetsusaponin IVa (50-100 mg/kg; from day 28 to day 40) shows anti-inflammatory and osteoprotective effects on rheumatoid arthritis via the JAK/STAT signaling pathway in mice[5].
Chikusetsusaponin IVa (50 mg/kg; i.g.; 8 weeks) can improve the symptoms of mice with high-fat diet (HFD)-induced metabolic dysfunction-associated steatotic liver disease (MASLD)[6].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Chikusetsusaponin Iva
- Cat. No.:
- HY-N0818
- Quantity:
Your information is safe with us.